In terms of vaccines, research has not yet developed an authorized product that can be used on a large scale against malaria, although there are several possible candidates.
Currently, the experimental RTS, S / AS01 vaccine against Plasmodium falciparum is in an advanced clinical trial phase and the World Health Organization could add it to other malaria control tools starting from 2015. Under the trade name Mosquirix ®, this drug has already been approved by the EMA - the European Medicines Agency - in July 2015.
Plasmodium falciparum is prevalent in Africa, in South East Asia, in the Pacific and in the Amazon basin; the vaccine could further reduce the victims of the malignant form of malaria, for which it is responsible.
